Embed Size (px)
Citation preview
Validation of RANO Criteria: Contribution of T2/FLAIR Assessment in Patients with Recurrent Glioblastoma Treated with Bevacizumab
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Background
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Slide 3
Presented By Raymond Huang at 2014 ASCO Annual Meeting
RANO Criteria
Presented By Raymond Huang at 2014 ASCO Annual Meeting
BRAIN trial (AVF3708g)
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Study design
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Response
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Inter-reader agreement
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Objective Response Rate
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Landmark analysis: Objective response versus Survival
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Progression
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Progression
Presented By Raymond Huang at 2014 ASCO Annual Meeting
PFS: Macdonald vs RANO
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Landmark analysis: Progression vs Overall Survival
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Conclusions
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Future directions
Presented By Raymond Huang at 2014 ASCO Annual Meeting
Acknowledgement
Presented By Raymond Huang at 2014 ASCO Annual Meeting
![Amino acid transporter LAT1 in tumor-associated vascular ...patients with bevacizumab, an anti-VEGF antibody, increased the PlGF in plasma [3]. FGF-2 and PlGF were increased in glioblastoma](https://img.dokumen.tips/doc/110x75/609eaca54cba15523b358952/amino-acid-transporter-lat1-in-tumor-associated-vascular-patients-with-bevacizumab.jpg)
